Ibuprofen treatment versus gradual introduction of interferon β-1b in patients with MS

被引：25
|
作者：
Rice, GPA
Ebers, GC
Lublin, FD
Knobler, RL
机构：
[1] London Hlth Sci Ctr, London, ON N6A 5A5, Canada
[2] Med Coll Penn & Hahnemann Univ, Philadelphia, PA USA
[3] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
来源：
NEUROLOGY | 1999年 / 52卷 / 09期
关键词：
D O I：
10.1212/WNL.52.9.1893
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Flu-like symptoms and injection site reactions are adverse effects of treatment with interferon beta-1b in patients with MS. We compared gradual dose escalation, ibuprofen treatment, or their combination in an open-label study. The combination reduced the incidence of flu-like symptoms to rates comparable with the placebo group in the pivotal trial but increased the frequency of injection site reactions, albeit modestly and transiently.
引用
收藏
页码：1893 / 1895
页数：3
相关论文
共 50 条
  • [1] Ibuprofen treatment versus gradual introduction of interferon β-1b in patients with MS
    Río, J
    Montalban, X
    NEUROLOGY, 2000, 54 (08) : 1710 - 1710
  • [2] Treatment of childhood and adolescent MS with interferon-β-1b
    Krupp, L
    Banwell, B
    Boiko, A
    Eraksoy, M
    Freedman, M
    Pohl, D
    Reder, AT
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S245 - S245
  • [3] Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b
    Giovannoni, G
    NEUROLOGY, 2003, 61 (07) : 1025 - 1025
  • [4] Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are cross-reactive
    Khan, OA
    Dhib-Jalbut, SS
    NEUROLOGY, 1998, 51 (06) : 1698 - 1702
  • [5] Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b
    Polman, C
    Kappos, L
    White, R
    Dahlke, F
    Beckmann, K
    Pozzilli, C
    Thompson, A
    Petkau, J
    Miller, D
    NEUROLOGY, 2003, 60 (01) : 37 - 43
  • [6] Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies
    Deisenhammer, F
    Reindl, M
    Harvey, J
    Gasse, T
    Dilitz, E
    Berger, T
    NEUROLOGY, 1999, 52 (06) : 1239 - 1243
  • [7] Liver and thyroid function and autoimmunity during interferon-β1b treatment for MS
    Durelli, L
    Ferrero, B
    Oggero, A
    Verdun, E
    Ghezzi, A
    Montanari, E
    Zaffaroni, M
    Milanese, C
    NEUROLOGY, 2001, 57 (08) : 1363 - 1370
  • [8] Interferon-β1b in the treatment of secondary progressive MS -: Impact on quality of life
    Freeman, JA
    Thompson, AJ
    Fitzpatrick, R
    Hutchinson, M
    Miltenburger, C
    Beckmann, K
    Dahlke, F
    Kappos, L
    Polman, C
    Pozzilli, C
    NEUROLOGY, 2001, 57 (10) : 1870 - 1875
  • [9] Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
    Fernandez, Oscar
    Agueera, Javier
    Izquierdo, Guillermo
    Millan-Pascual, Javier
    Ramio i Torrenta, Lluis
    Oliva, Pedro
    Argente, Javier
    Berdei, Yasmina
    Maria Soler, Jose
    Carmona, Olga
    Maria Errea, Jose
    Farres, Jordi
    PLOS ONE, 2012, 7 (05):
  • [10] Treatment of patients with secondary progressive multiple sclerosis with interferon β-1b
    Robert P. Lisak
    Current Neurology and Neuroscience Reports, 2001, 1 (3) : 246 - 248
12345